-transparent.png){kind=logo}
Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair. 2001
Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada. L.Panasci@hotmail.com
Various mechanisms have been implicated in nitrogen mustard drug resistance. The role of these mechanisms in the development of chlorambucil drug resistance in chronic lymphocytic leukemia (CLL) is discussed. We review these mechanisms with emphasis on the emerging role of DNA repair, and specifically, recombinational repair. Inhibition of these repair processes may lead to new therapies, not only in CLL, but in other malignancies as well.
Related Publications
L Panasci, and
J P Paiement, and
G Christodoulopoulos, and
A Belenkov, and
A Malapetsa, and
R Aloyz
May 2002,
Biochemical pharmacology,
L Panasci, and
J P Paiement, and
G Christodoulopoulos, and
A Belenkov, and
A Malapetsa, and
R Aloyz
September 2007,
Current oncology reports,
L Panasci, and
J P Paiement, and
G Christodoulopoulos, and
A Belenkov, and
A Malapetsa, and
R Aloyz
January 1991,
Leukemia research,
L Panasci, and
J P Paiement, and
G Christodoulopoulos, and
A Belenkov, and
A Malapetsa, and
R Aloyz
February 1989,
Cancer research,
L Panasci, and
J P Paiement, and
G Christodoulopoulos, and
A Belenkov, and
A Malapetsa, and
R Aloyz
April 1995,
Cancer letters,
L Panasci, and
J P Paiement, and
G Christodoulopoulos, and
A Belenkov, and
A Malapetsa, and
R Aloyz
January 1973,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
L Panasci, and
J P Paiement, and
G Christodoulopoulos, and
A Belenkov, and
A Malapetsa, and
R Aloyz
March 1973,
Cancer,
L Panasci, and
J P Paiement, and
G Christodoulopoulos, and
A Belenkov, and
A Malapetsa, and
R Aloyz
May 1998,
The New England journal of medicine,
L Panasci, and
J P Paiement, and
G Christodoulopoulos, and
A Belenkov, and
A Malapetsa, and
R Aloyz
September 2005,
Clinical lymphoma & myeloma,
L Panasci, and
J P Paiement, and
G Christodoulopoulos, and
A Belenkov, and
A Malapetsa, and
R Aloyz
April 2022,
Clinical advances in hematology & oncology : H&O,
